Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dovramilast for leprosy type 2 reaction
PACTR202610617672893Phase 2Recruiting
- Sponsor
- Medicines Development for Global Health
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2 trial of dovramilast in erythema nodosum leprosum (ENL) (3 arms), sponsored by Medicines Development for Global Health. Started Sep 2026; status: recruiting.
02
Drugs
dovramilast
03
Conditions
erythema nodosum leprosum (ENL)
Beyond the preview
Go deeper on PACTR202610617672893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610617672893.